Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter phase 4 study of rhTNFR-Ig for juvenile idiopathic arthritis
ChiCTR2000035016Phase 4Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Jul 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of etanercept in juvenile idiopathic arthritis (JIA) and juvenile idiopathic arthritis, enthesitis-related (JIA-ERA), sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoints: cJADAS and Joint imaging. Started Jul 2020; status: recruiting.
02
Drugs
etanercept
03
Conditions
juvenile idiopathic arthritis (JIA)juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)
Beyond the preview
Go deeper on ChiCTR2000035016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035016.